



OPEN ACCESS

Original research

Outcomes and regional differences in practice in a worldwide coronary stent registry

Murat Cimci,¹ Jawed Polad,² Mamas Mamas ,^{3,4} Andres Iniguez-Romo,⁵ Bernard Chevalier,⁶ Rajpal Abhaichand,⁷ Adel Aminian,⁸ Ariel Roguin,^{9,10} Gabriel Maluenda,¹¹ Michael Angioi,¹² Graham Cassel,¹³ Soichi Kuramitsu ,¹⁴ Lotte Jacobs,¹⁵ Roxane Debrus,¹⁵ Fazila Malik,¹⁶ David Hildick-Smith ,¹⁷ Peep Laanmets,¹⁸ Marco Roffi ¹

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/heartjnl-2021-320116>).

For numbered affiliations see end of article.

Correspondence to

Dr Marco Roffi, University Hospitals Geneva, Geneva, Switzerland; marco.roffi@hcuge.ch

Received 15 August 2021
Accepted 8 November 2021

ABSTRACT

Objective The primary objective was to assess the performance of a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer in an all-comer population. The secondary objective was to detail differences in contemporary percutaneous coronary intervention (PCI) practice worldwide.

Methods e-Ultimaster was an all-comer, prospective, global registry (NCT02188355) with independent event adjudication enrolling patients undergoing PCI with the study stent. The primary outcome measure was target lesion failure (TLF) at 1 year, defined as the composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion revascularisation. Data were stratified according to 4 geographical regions.

Results A total of 37 198 patients were enrolled (Europe 69.2%, Asia 17.8%, Africa/Middle East 6.6% and South America/Mexico 6.5%) and 1-year follow-up was available for 35 389 patients (95.1%). One-year TLF occurred in 3.2% of the patients, ranging from 2% (Africa/Middle East) to 4.1% (South America/Mexico). In patients with acute coronary syndrome, potent P2Y₁₂ inhibitors were prescribed in 48% of patients at discharge, while at 1 year 72% were on any dual antiplatelet therapy. Lipid-lowering treatment was administered in 80.9% and 75.5% of patients at discharge and 1 year, respectively. Regional differences in the profile of the treated patients as well as in PCI practice were reported.

Conclusions In this investigation with worldwide representation, contemporary PCI using a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer was associated with low 1-year TLF across clinical presentations and continents. Suboptimal adherence to current recommendations around antiplatelet and lipid lowering treatments was detected.

INTRODUCTION

Percutaneous coronary intervention (PCI) is the most common modality of coronary revascularisation and among the most frequently performed therapeutic procedures in medicine.¹ While PCI has been extensively studied in large-scale national registries²⁻⁴ as well as in randomised controlled trials comparing it with medical management or

coronary artery bypass surgery,⁵⁻⁷ comparative data on contemporary PCI practice across the globe are lacking. The main purpose of the e-Ultimaster registry was to assess the performance of a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer in an all-comer patient population worldwide to complement the favourable data generated in randomised controlled trials.^{8,9} A secondary objective of this analysis was to describe contemporary PCI practice worldwide.

METHODS

Study design

The e-Ultimaster registry (NCT02188355) was an all-comer, single-arm, prospective, multicentre study, with clinical follow-up at 3 months and 1 year, evaluating the performance of a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer (Ultimaster; Terumo Corporation, Tokyo, Japan) in daily practice. Patients were enrolled between October 2014 and June 2018 in 378 hospitals from 50 countries (online supplemental table 1). Follow-up was performed at 3 months at 1 year, by phone or hospital visit. Information collected included vital status, occurrence of adverse events, angina status, antiplatelet medication and other cardiac medication. Sites were instructed to attempt three phone calls and one contact by letter to obtain follow-up information before patient was considered lost to follow-up. For the purpose of the analysis, countries were grouped in four geographical regions: Europe, Asia, South America/Mexico and Africa/Middle East (online supplemental figure 1 and online supplemental table 2). No patient or public was involved in the design or execution of the study.

Study population and device

All patients ≥18 years old undergoing PCI using a drug-eluting stent according to local hospital practice and with the intention to be implanted with the study stent were eligible. The registry was conducted in accordance with the Declaration of Helsinki and country-specific regulatory requirements. The study protocol was reviewed and approved by the Institutional Review Board/Ethics Committee of each participating centre and



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Cimci M, Polad J, Mamas M, *et al.* *Heart* Epub ahead of print: [please include Day Month Year]. doi:10.1136/heartjnl-2021-320116




Figure 1 Flow chart of the study population. The 1-year follow-up population included patients who had event that contributed to the primary outcome measure, died during follow-up or completed 1-year follow-up. DES, drug-eluting stent.

all patients signed the informed consent form. The study population used to analyse clinical outcomes during follow-up includes all patients who received one or more study stents on enrolment and (1) completed 1 year follow-up or (2) who reached the primary outcome measure or (3) who died during follow-up. The Ultimaster coronary stent system is a new generation open-cell cobalt–chromium thin-strut (80 µm) sirolimus-eluting stent with an abluminal biodegradable polymer coating (poly-D,L-lactic acid polycaprolactone).¹⁰ Sirolimus is released over a 3-month to 4-month period after which the polymer coating is fully degraded.

Clinical outcomes

The primary outcome measure was target lesion failure (TLF) at 1 year, defined as a composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion

Table 1 Baseline patient characteristics

Patient characteristics	All regions n=37 198	Europe n=25 736	Asia n=6614	Africa/Middle East n=2438	South America/Mexico n=2410
Age, years	64.2±11.3 (37 198)	65.5±11.1 (25 736)	60.9±10.9 (6614)*	59.6±11.4 (2438)*	63.3±10.9 (2410)*
Octogenarians (≥80 years)	8.8% (3286/37 198)	10.7% (2757/25 736)	4.3% (281/6614)*	4.2% (102/2438)*	6.1% (146/2410)*
Gender, male	76.0% (28 257/37 198)	75.7% (19 486/25 736)	76.3% (5049/6614)	79.9% (1947/2438)*	73.7% (1775/2410)*
Body mass index, kg/m ²	27.8±4.6 (29 946)	28.1±4.7 (21 612)	26.3±4.3 (4735)*	28.3±4.6 (1718)*	27.8±4.4 (1881)*
≤18.5	0.7% (222/29 946)	0.6% (128/21 612)	1.6% (74/4735)*	0.5% (8/1718)	0.6% (12/1881)
18.5–24.9	27.7% (8295/29 946)	25.5% (5502/21 612)	40.1% (1900/4735)*	23.0% (395/1718)*	26.5% (498/1881)
25–29.9	44.4% (13 293/29 946)	44.9% (9700/21 612)	41.2% (1951/4735)*	46.1% (792/1718)	45.2% (850/1881)
≥30	27.2% (8136/29 946)	29.1% (6282/21 612)	17.1% (810/4735)*	30.4% (523/1718)	27.7% (521/1881)
Cardiovascular risk factors, n†	2.1±0.9 (32 006)	2.1±0.9 (22 399)	2.0±0.9 (5250)*	2.2±1.0 (2231)*	2.1±0.9 (2126)
Diabetes mellitus	28.4% (10 379/36 572)	24.9% (6272/25 192)	32.2% (2114/6564)*	47.0% (1140/2428)*	35.7% (853/2388)*
Insulin dependent	20.4% (2121/10 379)	20.0% (1255/6272)	14.0% (296/2114)*	28.1% (320/1140)*	29.3% (250/853)*
Non-insulin dependent	79.5% (8249/10 379)	79.9% (5012/6272)	86.0% (1817/2114)*	71.7% (817/1140)*	70.7% (603/853)*
Unknown	0.09% (9/10 379)	0.08% (5/6272)	0.05% (1/2114)	0.3% (3/1140)	0.0% (0/853)
Smoking					
Never	37.0% (12 380/33 480)	33.9% (8075/23 848)	48.9% (2644/5408)*	42.1% (923/2193)*	36.3% (738/2031)*
Previous	29.0% (9711/33 480)	31.1% (7417/23 848)	19.9% (1078/5408)*	22.3% (490/2193)*	35.8% (726/2031)*
Current	23.6% (7897/33 480)	24.3% (5796/23 848)	19.0% (1025/5408)*	29.5% (647/2193)*	21.1% (429/2031)*
Unknown	10.4% (3492/33 480)	10.7% (2560/23 848)	12.2% (661/5408)	6.1% (133/2193)	6.8% (138/2031)
Hypertension	67.8% (22 840/33 684)	66.1% (15 624/23 632)	72.4% (4127/5698)*	64.1% (1445/2255)	78.3% (1644/2099)*
Hypercholesterolemia	59.9% (19 462/32 479)	61.6% (14 295/23 202)	55.1% (2797/5081)*	55.6% (1230/2211)*	57.4% (1140/1985)*
Family history of heart disease	36.2% (7259/20 081)	39.5% (5604/14 178)	20.7% (678/3274)*	35.9% (536/1494)*	38.9% (441/1135)
Previous MI	22.8% (7852/34 423)	21.5% (5239/24 392)	28.0% (1601/5727)*	20.8% (462/2220)	26.4% (550/2084)*
Previous revascularisation	29.1% (10 027/34 522)	29.2% (7127/24 442)	25.6% (1468/5744)*	30.9% (695/2253)	35.4% (737/2083)*
Previous PCI	26.0% (9026/34 687)	26.2% (6425/24 559)	23.3% (1342/5767)*	28.3% (642/2267)*	29.5% (617/2094)*
Previous CABG	5.6% (1938/34 562)	5.7% (1387/24 514)	3.3% (191/5745)*	6.0% (135/2255)	11.0% (225/2048)*
Atrial fibrillation on OAC	5.6% (1925/34 450)	6.8% (1651/24 359)	2.6% (150/5743)*	3.0% (69/2283)*	2.7% (55/2065)*
Previous stroke	5.4% (1879/34 577)	5.8% (1415/24 501)	5.8% (328/5682)	2.6% (60/2314)*	3.7% (76/2080)*
Peripheral vascular disease	6.7% (2255/33 880)	7.3% (1758/23 958)	5.1% (286/5655)*	5.9% (131/2222)*	3.9% (80/2045)*
Congestive heart failure	11.36% (3823/33 649)	9.5% (2255/23 821)	23.6% (1312/5552)*	6.1% (136/2242)*	5.9% (120/2034)*
Renal impairment	7.00% (2548/36 407)	6.9% (1731/25 134)	8.0% (522/6547)*	5.5% (128/2333)*	7.0% (167/2393)
Clinical presentation					
CCS	44.9% (16 672/37 171)	44.7% (11 482/25 715)	48.4% (3199/6613)*	42.0% (1024/2436)*	40.2% (967/2407)*
NSTE-ACS	35.0% (12 992/37 171)	35.7% (9191/25 715)	31.2% (2064/6613)*	37.6% (915/2436)	34.2% (822/2407)
STEMI	20.2% (7507/37 171)	19.6% (5042/25 715)	20.4% (1350/6613)	20.4% (497/2436)	25.7% (618/2407)*

Data are mean±SD for continuous variables with or % (n) for categorical variables. The number of patients with available data is indicated in brackets. The p value for the comparison over all four regions was <0.0001 for all variables.

Renal impairment: defined as estimated glomerular filtration rate <60 mL/min/1.73 m². Cardiovascular risk factors include diabetes, current smoking, hypertension, hypercholesterolemia and family history of CV disease

*Indicates a p value <0.05 for the difference in characteristics between the region as compared to Europe.

†Defines diabetes, current smoking, hypertension, hypercholesterolemia and family history of heart disease.

CABG, coronary artery bypass graft; CCS, chronic coronary syndromes; CV, cardiovascular; MI, myocardial infarction; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction.

Table 2 Coronary artery disease at angiography and characteristics of the treated lesions

	All regions n=37 198	Europe n=25 736	Asia n=6614	Africa/Middle East n=2438	South America/Mexico n=2410
Extension of coronary disease					
Multivessel disease	46.1% (17 147/37 198)	45.4% (11 627/25 736)	46.9% (3104/6614)*	54.7% (1334/2438)*	43.0% (1037/2410)*
1-vessel disease	53.8% (20 029/37 198)	54.6% (14 062/25 736)	53.1% (3509/6614)*	45.2% (1101/2438)*	56.3% (1357/2410)
2-vessel disease	29.2% (10 867/37 198)	29.8% (7660/25 736)	26.3% (1738/6614)*	32.5% (792/2438)*	28.1% (677/2410)
3-vessel disease	16.9% (6269/37 198)	15.6% (4007/25 736)	20.6% (1364/6614)*	22.2% (541/2438)*	14.8% (357/2410)
Vessel treated					
Left main	3.1% (1158/37 198)	3.2% (825/25 736)	2.7% (179/6614)*	2.6% (63/2438)	3.8% (91/2410)
LAD	51.6% (19 177/37 198)	50.7% (13 048/25 736)	51.7% (3420/6614)	58.9% (1436/2438)*	52.8% (1273/2410)*
CFX	27.8% (10 343/37 198)	28.0% (7195/25 736)	25.1% (1660/6614)*	33.7% (822/2438)*	27.6% (666/2410)
RCA	34.3% (12 765/37 198)	34.5% (8878/25 736)	33.5% (2214/6614)	35.5% (865/2438)	33.5% (808/2410)
Graft (arterial or venous)	1.2% (444/37 198)	1.4% (355/25 736)	0.4% (29/6614)*	1.4% (33/2438)	1.1% (27/2410)
Lesion characteristics					
N of lesions identified, per patient	1.8±1.1 (37 176)	1.8±1.1 (25 734)	1.9±1.2 (6613)*	2.0±1.1 (2435)*	1.8±1.0 (2394)*
N of lesions treated, per patient	1.3±0.6 (37 158)	1.3±0.6 (25 729)	1.2±0.5 (6605)*	1.5±0.7 (2432)*	1.3±0.6 (2392)
Lesion characteristics, per patient					
CTO	5.1% (1884/37 198)	4.6% (1195/25 736)	6.5% (428/6614)*	4.5% (109/2438)	6.3% (152/2410)*
Bifurcation	11.8% (4395/37 198)	13.1% (3361/25 736)	7.8% (515/6614)*	11.9% (290/2438)	9.5% (229/2410)*
Small vessels	43.7% (16 241/37 198)	42.8% (11 016/25 736)	43.2% (2858/6614)	48.8% (1190/2438)*	48.8% (1177/2410)*
Long lesions	37.3% (13 885/37 198)	34.8% (8960/25 736)	41.9% (2768/6614)*	45.9% (1120/2438)*	43.0% (1037/2410)*
Lesion characteristics, per lesion					
ACC/AHA classification					
Type B2 lesion	22.0% (10 923/49 751)	22.2% (7721/34 797)	20.4% (1642/8033)*	16.5% (605/3659)*	29.3% (955/3262)
Type C lesion	20.6% (10 246/49 751)	20.6% (7165/34 797)	21.6% (1733/8033)	17.0% (622/3659)*	22.3% (726/3262)
Ostial lesions	5.6% (2780/49 347)	5.9% (2044/34 427)	4.2% (337/8032)*	6.4% (232/3642)	5.1% (167/3246)
Moderate/severe calcification	18.1% (8930/49 347)	19.4% (6667/34 427)	9.5% (762/8032)*	15.1% (550/3642)*	29.3% (951/3246)

Data are mean±SD for continuous variables with or % (n) for categorical variables. The number of patients with available data is indicated in brackets. The p value for the comparison over all 4 regions was <0.0001 for all variables, except for left main (overall p=0.017) and RCA (overall p=0.21). A * indicates a p value <0.05 for the difference in characteristics between the region as compared with Europe.

Lesion characteristics at index procedure are reported. Small vessels are defined as at least 1 stent with diameter ≤2.75 mm. Long lesions are defined as at least 1 stent with length ≥25 mm. ACC/AHA, American College of Cardiology/American Heart Association; CFX, circumflex; CTO, chronic total occlusion; LAD, left anterior descending artery; RCA, right coronary artery.

revascularisation (endpoint definitions reported in online supplemental table 3). Prespecified secondary outcome measures included any death, cardiac death, myocardial infarction, target lesion revascularisation, target vessel revascularisation, target vessel failure (composite of cardiac death, target vessel myocardial infarction and target vessel revascularisation), the composite of any death, any myocardial infarction and any coronary revascularisation, stent thrombosis, and major vascular and bleeding complications. A clinical events committee reviewed and adjudicated all the reported adverse events possibly related to death, myocardial infarction, target lesion or target vessel revascularisation and stent thrombosis (online supplemental table 4). For the purpose of the study, length of stay was defined as [(date of discharge–date of procedure)+1]; that is, length of stay=1 means discharge on the same day of the procedure.

Statistical analysis

Patient demographics, comorbidities, target lesion characteristics, procedural characteristics and medication use were analysed per geographical region and were summarised using mean±SD for continuous variables and frequencies and percentages for categorical variables. A comparison was made over all regions, using ANOVA (if variances were equal) or Welch test (if variances were unequal) for continuous variables and χ^2 test for categorical variables. In addition, comparisons were made between each region and Europe, using Student's t-test (parametric) or Kruskal-Wallis test (non-parametric) for continuous variables and χ^2 test or Fisher exact test for categorical variables. A univariate logistic regression model was used to calculate the OR with 95% CI for primary and secondary outcome

measures for each region as compared with Europe. To identify predictors of the primary outcome measure, a stepwise logistic regression model was used with p values to enter and stay in the model set to p=0.25 and p=0.10, respectively. The variables entered in the model were age, sex, body mass index, diabetes mellitus, hypertension, hypercholesterolemia, smoking, renal failure, previous PCI, previous coronary artery bypass surgery, previous myocardial infarction, non-ST-elevation acute coronary syndromes (NSTE-ACS), ST-elevation myocardial infarction (STEMI), multivessel disease, number of lesion identified, number of lesions treated, treated vessel, bifurcation, chronic total occlusion, in-stent restenosis, ostial lesions, moderate to severe calcification, AHA/ACC lesion type, small vessels, long lesions, number of implanted study stents, length of implanted study stent, radial access and geographical region. Missing values were imputed with the mean value of the selected group. Statistical analyses were performed using SAS software, V.9.4 (SAS Institute, Inc., Cary, NC, USA).

RESULTS

Patient and procedural characteristics

A total of 37 198 patients were included in the study and 35 389 patients (95.1%) completed 1-year follow-up (figure 1). With respect to regional distribution, 25 736 (69.2%), 6614 (17.8%), 2438 (6.6%) and 2410 (6.5%) patients were enrolled in Europe, Asia, Africa/Middle East and South America/Mexico, respectively. Patient's characteristics stratified per region of enrolment are summarised in table 1. The majority of the patients across the continents were treated for ACS, while




Figure 2 Radial access according to clinical presentation per region. CCS, chronic coronary syndrome; NSTEMI-ACS, non-ST-segment elevation acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction.

STEMI patients comprised 20.2% of the overall cohort. Details on coronary artery disease at angiography and on the characteristics of the lesions treated are reported in table 2.

The proportion of patients undergoing PCI via transradial access ranged from 50.2% (Africa/Middle East) to 88.1% (Europe). This access route was used in 80.1% of patients with chronic coronary syndromes (CCS), 84.3% of patients with NSTEMI-ACS and 83.5% of patients with STEMI ($p < 0.001$) (figure 2). Technical details on the PCI procedure are reported in online supplemental table 5. In the vast majority of cases, the procedure consisted of solely balloon angioplasty and stenting, while the use of additional devices such as atherectomy or




Figure 3 Dual antiplatelet therapy at discharge and at follow-up according to clinical indication. ACS, acute coronary syndrome; CCS, chronic coronary syndrome; DAPT, dual antiplatelet therapy.




Figure 4 Lipid-lowering treatment in the overall patient population.

cutting balloons was limited to 1.1% or less of the procedures in all continents. Balloon dilatation prior to stent deployment (ie, pre-dilatation) was performed in 51.4% (Africa/Middle East) to 59.3% of lesions (South America/Mexico), while balloon post-dilatation to optimise stent expansion was applied in 37.4% (South America/Mexico) to 47.5% (Asia) of lesions. In STEMI, thrombus aspiration was performed in 9.4% (Africa/Middle East) to 21% of the patients (Asia), while in saphenous vein graft interventions, distal protection was applied in 5.4% of cases. Intravascular imaging was rarely used, with the exception of Japan (97.5% use) (online supplemental figure 2). The use of closure devices for femoral access ranged from 9.6% (Asia) to 72.6% (Europe).

Antithrombotic and lipid-lowering treatments

The use of unfractionated heparin during PCI exceeded 90% across the continents, with the exception of Asia, where low molecular weight heparin was used in 31% of the cases (in 11% in patients with CCS and in 46% in patients with ACS) (online supplemental table 6). Intravenous glycoprotein IIb/IIIa receptor inhibitors were used in less than 2% and 10% of PCI for CCS and ACS, respectively. The use of dual antiplatelet therapy (DAPT) at discharge, 3 months and 1 year stratified for the clinical presentation across the continents are depicted in figure 3 and online supplemental table 7. Potent P2Y₁₂ inhibitors at discharge were administered in 48.0% of patients with ACS (online supplemental table 7 and online supplemental figure 3). A total of 6.1% of patients were discharged on oral anticoagulants, ranging from 2.0% (South America/Mexico) to 7.5% (Europe). Prescription of lipid-lowering therapy (ie, of any lipid-lowering agent) in the overall population was 80.9% at discharge and 75.5% at 1 year (figure 4). Rates of lipid-lowering agents at 1 year according to region and clinical presentation are reported in online supplemental table 8.

Periprocedural complications, length of stay and 1-year clinical outcomes

Angiographic complications, defined as coronary perforation or spasm, no reflow, side branch occlusions or residual thrombus, occurred in 2.3%, 3.1% and 5.2% in patients presenting with CCS, NSTEMI-ACS and STEMI, respectively ($p < 0.0001$). Online supplemental table 9 reports the event rates stratified per clinical presentation and geographical region. The median (10th–90th percentile) length of hospital stay post-procedure ranged from 2 (1–4) for patients with CCS to 3 (1–7) for NSTEMI-ACS, and 4 (2–10) for patients with STEMI. Regional data for length of hospital stay post-procedure are reported in online supplemental table 10. The primary outcome measure of the study, TLF at 1 year, occurred in 3.2% of the patients, while definite

Table 3 One-year clinical outcomes

	All regions n=35 389	Europe n=24 819	Asia n=6305	Africa/Middle East n=2081	South America/Mexico n=2184	P value
Target lesion failure†	3.2% (1135/35 389)	3.5% (867/24 819)	2.2% (137/6305)*	2.0% (41/2081)*	4.1% (90/2184)	<0.0001
Cardiac death†	1.3% (455/35 389)	1.3% (320/24 819)	0.9% (59/6305)*	0.9% (19/2081)	2.6% (57/2184)*	<0.0001
Target vessel MI†	0.9% (316/35 389)	1.1% (271/24 819)	0.4% (22/6305)*	0.6% (13/2081)*	0.5% (10/2184)*	<0.0001
Clinically driven TLR†	1.7% (591/35 389)	1.9% (458/24 819)	1.2% (78/6305)*	1.1% (22/2081)*	1.5% (33/2184)	<0.0001
All-cause death†	2.1% (746/35 389)	2.2% (539/24 819)	1.6% (101/6305)*	1.4% (28/2081)*	3.6% (78/2184)*	<0.0001
All MI†	1.2% (423/35 389)	1.5% (361/24 819)	0.4% (25/6305)*	1.1% (22/2081)	0.7% (15/2184)*	<0.0001
Revascularisations						
TVR†	2.4% (830/35 389)	2.6% (655/24 819)	1.6% (100/6305)*	1.4% (28/2081)*	2.2% (47/2184)	<0.0001
TV non-TLR†	0.7% (261/35 389)	0.9% (226/24 819)	0.3% (17/6305)*	0.3% (6/2081)*	0.6% (12/2184)	<0.0001
TLR†	1.7% (614/35 389)	1.9% (469/24 819)	1.4% (86/6305)*	1.1% (23/2081)*	1.7% (36/2184)	<0.0001
Clinically driven revascularisations						
TVR†	2.3% (800/35 389)	2.6% (638/24 819)	1.4% (91/6305)*	1.3% (27/2081)*	2.0% (44/2184)	<0.0001
TV non-TLR*	0.7% (252/35 389)	0.9% (218/24 819)	0.3% (16/6305)*	0.3% (6/2081)*	0.6% (12/2184)	<0.0001
Target vessel failure*	3.7% (1308/35 389)	4.1% (1016/24 819)	2.4% (148/6305)*	2.2% (46/2081)*	4.5% (98/2184)	<0.0001
Stent thrombosis†						
Definite †	0.4% (146/35 389)	0.5% (125/24 819)	0.1% (9/6305)*	0.2% (4/2081)*	0.4% (8/2184)	<0.0001
Probable†	0.3% (94/35 389)	0.2% (60/24 819)	0.2% (13/6305)	0.2% (4/2081)	0.8% (17/2184)*	<0.0001
Definite/probable†	0.7% (238/35 389)	0.7% (183/24 819)	0.4% (22/6305)*	0.4% (8/2081)	1.1% (25/2184)*	<0.0001
Possible†	0.5% (190/35 389)	0.6% (141/24 819)	0.4% (23/6305)*	0.4% (8/2081)	0.8% (18/2184)	<0.0001
All bleedings	2.9% (1013/35 389)	3.7% (923/24 819)	0.6% (36/6305)*	0.7% (15/2081)*	1.8% (39/2184)*	<0.0001
BARC 2–5 bleeding	2.1% (743/35 389)	2.7% (675/24 819)	0.5% (29/6305)*	0.6% (12/2081)*	1.2% (27/2184)	<0.0001
BARC 3–5 bleeding	0.9% (304/35 389)	1.1% (265/24 819)	0.2% (14/6305)*	0.4% (8/2081)*	0.8% (17/2184)	<0.0001

Events are reported as % (n) in the patient population that reached 1-year follow-up, died during follow-up or who had event that contributed to the primary outcome measure (n=35 389). The p value is given for the comparison over all 4 regions.

Target lesion failure: composite of cardiac death, TV-MI or clinically driven TLR. Target vessel failure: composite of cardiac death, TV-MI or clinically driven TVR.

*Indicates a p value <0.05 for the difference in characteristics between the region as compared with Europe.

†Events were adjudicated by an independent Clinical Event Committee.

MI, myocardial infarction; TV non-TLR, target vessel but non-target lesion revascularisation; TLR, target lesion revascularisation; TVR, target vessel revascularisation.

or probable stent thrombosis and bleedings at 1 year occurred in 0.7% and 2.9% of the patients, respectively. Table 3 summarises the 1-year clinical outcomes stratified per region while the corresponding event rates according to clinical presentations are reported in online supplemental tables 11–13. Independent predictors of TLF at 1 year are reported in table 4.

DISCUSSION

The main finding of e-Ultimaster, a global registry with independent event adjudication, was that PCI performed with a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer was associated with low rates of TLF at 1 year across patient's clinical presentations and continents (<5% for virtually all analyses). Device safety was remarkable with a definite or probable stent thrombosis rate at 1 year <1%. These results expand to an all comer and far bigger population treated in clinical practice the favourable outcomes of PCI with the same device observed in randomised controlled trials, which have previously shown a 1-year TLF rate of 5.4% among 551 patients with stable and unstable coronary disease and a 1-year TLF rate of 6.1% among 375 patients with STEMI.^{9–11} Independent predictors of 1-year TLF in our study included clinical characteristics such as age, diabetes, renal insufficiency, ACS at presentation and previous revascularisation as well as lesion-specific and procedural predictors, all markers of disease complexity. The performance of PCI in Europe, as compared with Asia and Africa/Middle East, was associated with an increased risk of TLF. The observational nature of the study does not allow conclusion on whether this finding may be due to differences in technique, case selection or unmeasured confounders.

The true global nature of the study allowed for an unprecedented simultaneous assessment of current PCI practices across different regions in the world. Accordingly, worldwide comparative data on contemporary PCI practices are lacking while available data are limited to few countries and specific aspects of the procedure, such as antiplatelet treatment or vascular access.^{12–13} Limitations of the few 'global' PCI studies included the use of first-generation drug-eluting stents or an enrolment essentially limited to Western countries.^{14–15} We detected major differences in the profile of patients undergoing PCI, procedural practices, pharmacological treatments and outcomes. With respect to the profile of the patients treated, the majority were men over the age of 60 years, while the proportion of octogenarians differed by more than a factor 2 across the continents. More than a quarter of the patients had diabetes, with the prevalence approaching half in Africa/Middle East. In accordance to current guidelines, the main indication for PCI across the continents was ACS.^{16–18} Our study showed that radial access has become the vascular access site of choice worldwide, with a use ranging from one out of two procedures in Africa/Middle East to virtually nine out of ten in Europe. While in Europe the use of radial approach was widely embraced for all clinical presentation, in Asia and Africa/Middle East this access route was more frequently used in patients with ACS than those with CCS. The choice of the transradial approach for the entire spectrum of clinical presentations is in line with recent guidelines and supported by our study, showing that the use of this vascular access site was protective with respect to 1-year TLF.¹⁹ For patients treated via a femoral approach, the use of vascular closure devices showed a great deal of variation, ranging from less than 10% in Asia to almost three-quarters of all cases in Europe. In the absence of adequately powered randomised

Table 4 Predictors for 1-year target lesion failure

Univariable				Multivariable			
Predictor	OR	95% CI	P value		OR	95% CI	P value
Region							
Europe vs Asia	1.63	1.36 to 1.96	<0.0001	Europe vs Asia	1.56	1.29 to 1.89	<0.0001
Europe vs Africa/Middle East	1.80	1.31 to 2.47	0.0003	Europe vs Africa/Middle East	2.01	1.45 to 2.79	<0.0001
Europe vs South America/Mexico	0.84	0.67 to 1.05	0.13	Europe vs South America/Mexico	0.91	0.72 to 1.14	0.39
Clinical							
Age (+10 years)	1.33	1.27 to 1.41	<0.0001	Age (+10 years)	1.17	1.10 to 1.24	<0.0001
Body mass index (+5 kg/m ²)	0.95	0.89 to 1.02	0.17	Body mass index (+5 kg/m ²)	0.93	0.87 to 1.01	0.073
Diabetes	1.62	1.43 to 1.83	<0.0001	Diabetes	1.44	1.26 to 1.64	<0.0001
Renal impairment	2.77	2.36 to 3.26	<0.0001	Renal impairment	1.92	1.62 to 2.29	<0.0001
Previous PCI	1.68	1.48 to 1.90	<0.0001	Previous PCI	1.42	1.23 to 1.63	<0.0001
Previous CABG	2.55	2.12 to 3.07	<0.0001	Previous CABG	1.30	1.03 to 1.65	0.027
NSTE-ACS	1.13	1.00 to 1.28	0.049	NSTE-ACS	1.20	1.05 to 1.38	0.0093
STEMI	1.04	0.90 to 1.21	0.57	STEMI	1.58	1.33 to 1.87	<0.0001
Multivessel disease	1.67	1.48 to 1.89	<0.0001				
Lesion/procedural							
No of lesions identified (+1)	1.33	1.27 to 1.39	<0.0001	No of lesions identified (+1)	1.24	1.17 to 1.31	<0.0001
No of lesions treated (+1)	1.30	1.19 to 1.41	<0.0001	No of lesions treated (+1)	0.81	0.70 to 0.93	0.0022
RCA treated	0.74	0.65 to 0.84	<0.0001	RCA treated	0.73	0.64 to 0.84	<0.0001
Left main treated	3.38	2.75 to 4.17	<0.0001	Left main treated	1.88	1.49 to 2.38	<0.0001
Graft treated	4.03	3.00 to 5.46	<0.0001	Graft treated	1.83	1.26 to 2.66	0.0016
Bifurcation	1.77	1.52 to 2.06	<0.0001	Bifurcation	1.32	1.12 to 1.56	0.0011
In-stent restenosis	1.73	1.40 to 2.04	<0.0001	In-stent restenosis	1.24	0.98 to 1.57	0.068
Moderate/severe calcification	1.50	1.31 to 1.71	<0.0001				
Lesion type B2	1.38	1.21 to 1.57	<0.0001				
Lesion type C	1.43	1.25 to 1.62	<0.0001				
Small vessels	1.23	1.10 to 1.39	0.0005				
Total stent length	1.008	1.006 to 1.011	<0.0001				
No of stents implanted (+1)	1.30	1.23 to 1.37	<0.0001	No of stents implanted (+1)	1.26	1.15 to 1.37	<0.0001
Radial access	0.73	0.64 to 0.85	<0.0001	Radial access	0.81	0.69 to 0.94	0.0066

CABG, coronary artery bypass graft; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction.

controlled trials, current guidelines do not provide recommendations in favour or against the use of those devices.

In our study, the PCI procedure consisted of solely balloon angioplasty and stenting in the vast majority of cases, while additional devices such as atherectomy or cutting balloons were rarely used (in 2% or less across the continents). We showed that balloon dilatation prior to stent implantation was more frequently performed than balloon post-dilatation (applied in less than half of the cases). Intravascular imaging was rarely performed, with the exception of Japan where it was used in the vast majority of procedures. The old and inexpensive unfractionated heparin remained the peri-procedural anticoagulant of choice across patient's clinical presentations and continents, being used in more than 9 out of 10 procedures.^{18 19} Glycoprotein IIb/IIIa receptor inhibitors were rarely administered, even in the setting of ACS. Virtually all patients received DAPT at discharge. However, approximately 1 out of 5 of patients presenting with CCS was discharged on ticagrelor or prasugrel instead of the guideline-recommended clopidogrel. In addition, DAPT was still administered in 2 out of 3 patients with CCS at 1 year, while the recommended DAPT duration for this indication is 6 months.²⁰ The proportion of patients with CCS on DAPT at 1 year was as high as 8 to 9 out of 10 patients in Asia, Africa/Middle East and South America/Mexico, although such a strategy has been associated with increased bleeding risk in the absence of an ischaemic benefit.²¹ Remarkable was the

finding that less than half of patients with ACS were discharged on a potent P2Y₁₂ inhibitor (ie, ticagrelor or prasugrel), with a proportion being as low as 1 in 7 in South America/Mexico. This was despite the strong recommendation in guidelines for both agents over clopidogrel.¹⁸ Likely explanation for this finding is that in some countries these agents may either not be commercialised or too expensive. In all regions, the prescription of ticagrelor surpassed by more than a factor 6 the one of prasugrel. The guideline-recommended DAPT duration of 1 year in ACS was prescribed in less than three quarters of the patients, with Europe showing the lowest rate (2 out of 3 patients), while in other continents the rate exceeded 80%.¹⁸ Although e-Ultimaster did not collect all the parameters allowing for a formal bleeding risk assessment, the risk profile of the patients (eg, mean age 64 years, renal insufficiency 7%, prior stroke 5%, need for oral anticoagulation 6%) and the low bleeding rates observed do not seem to justify earlier DAPT discontinuation. Our findings are in line with an international myocardial infarction registry showing that 1 patient out of 4 was not on DAPT at 1 year.¹³

Despite the wealth of data and the clear-cut recommendations for secondary prevention for lipid-lowering agents, our study demonstrates that lipid-lowering treatment was suboptimal, with approximately 1 in 5 and 1 in 4 patients not receiving lipid-lowering treatment at discharge and 1 year, respectively.²² Our findings reproduce on a global scale prior observation from national and multi-national registries.²³ Little is known about

differences in current length of stay following PCI across the globe. In our study, the post-procedural length of stay ranged considerably according to clinical presentation and geographical areas. The greatest variation was observed in the rate of same-day discharge among patients treated with PCI for CCS, ranging from 1/20 in Asia to 2/3 in South America/Mexico. Such differences cannot be explained by medical reasons alone and are likely related to specificities of the healthcare system and reimbursement issues. Notable was the variation in post-procedural length of stay we observed in patients with STEMI, ranging from a median of 4 days in Europe and Africa/Middle East to a median of 6 days in Asia.

Our study has several limitations inherent to the nature of the investigation. While the registry had no exclusion criteria other than age less than 18 years and unwillingness to sign the informed consent and encouraged the enrolment of a true all-comer population, the 1-year mortality observed is substantially lower than the one documented in other PCI datasets with systematic inclusion, revealing the selection of a low-risk population.^{24 25} While all deaths, myocardial infarctions, target lesion and target vessel revascularisations as well as stent thromboses were adjudicated by an independent clinical events committee, other outcome measures were not. Since the measurement of cardiac enzymes post-PCI was left at the discretion of the investigators according to local practice, the incidence of periprocedural myocardial infarctions may have been underestimated. While systematic online data monitoring was performed, underreporting of events cannot be excluded. Enrolment was not equally distributed among regions; however, even in regions less well represented, such as Africa/Middle East and South America/Mexico, the recruitment approached 2500 patients. In addition, practice in countries aggregated to a region were likely non-homogenous. As the study stent was not overall approved, countries with high PCI volumes such as the USA or China could not be included in the study. Finally, loss to follow-up (less than 5%) may have been

a source of bias. Baseline characteristics of patients with and without follow-up are reported in online supplemental table 14.

In summary, this study, unmatched to our knowledge in size as well as global representation, showed a remarkable performance of a new generation thin-strut biodegradable-polymer sirolimus-eluting stent, with low TLF as well as stent thrombosis rates at 1 year across clinical presentations and continents. Differences in PCI practice across the globe, such as in the use of transradial access, were outlined and suboptimal adherence to current recommendations on DAPT as well as lipid-lowering therapies were detected. Notable was the administration of DAPT 1 year post-PCI in the vast majority of patients with CCS in several regions of the world and the low prescription rate of potent P2Y₁₂ in patients with ACS. These findings are a call for standardisation of PCI practice and pharmacological treatment post-PCI. Tools to facilitate worldwide implementation of guideline-recommended treatments should be investigated.

Author affiliations

¹Division of Cardiology, University Hospitals Geneva, Geneva, Switzerland

²Department of Cardiology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands

³Keele Cardiovascular Research Group, Center for Prognosis Research, Keele University, Keele, UK

⁴Department of Cardiology, University Hospital of North Midlands, Stoke-on-Trent, UK

⁵Interventional Cardiology, Hospital Álvaro Cunqueiro, Vigo, Spain

⁶Ramsay Générale de Santé, Institut Cardiovasculaire Paris Sud, Massy, France

⁷Department of Cardiology, GKNM Hospital, Coimbatore, Tamil Nadu, India

⁸Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium

⁹Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel

¹⁰Faculty of Medicine, Technion Israel Institute of Technology The Ruth and Bruce Rappaport, Haifa, Israel

¹¹Cardiology, Hospital Clinico San Borja Arriaran, Santiago, Chile

¹²Clinique Louis Pasteur, Nancy, France

¹³Netcare Milpark Hospital, Johannesburg, South Africa

¹⁴Kokura Memorial Hospital, Kitakyushu, Japan

¹⁵Medical and Clinical Division, Terumo Europe NV, Leuven, Belgium

¹⁶National Heart Foundation Hospital and Research Institute, Dhaka, Bangladesh

¹⁷Cardiology, Royal Sussex Hospital, Brighton, UK

¹⁸North Estonia Medical Centre Foundation, Tallinn, Estonia

Key messages

What is already known on this subject?

- While randomised controlled trials have established the efficacy and safety of a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer, information on the performance of the device in a real-world setting are sparse. Although percutaneous coronary intervention (PCI) is one of the most frequently performed invasive therapeutic procedures in medicine, data on contemporary practice worldwide as well as on regional differences are lacking.

What might this study add?

- This study expands the favourable performance profile of the study stent observed in randomised controlled trials to an all-comer population in daily practice. In addition, it outlines differences in PCI practice worldwide and showed, among other findings, a suboptimal prescription of antiplatelet as well as lipid-lowering agents.

How might this impact on clinical practice?

- This study supports the use of a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer, independently of clinical presentation and local PCI practice. In addition, it calls for a better compliance with practice guidelines, in particular with respect to pharmacological treatment post-PCI.

Twitter Mamas Mamas @MMamas1973

Contributors MR is responsible for the overall content as the guarantor. MC interpreted the results and drafted the manuscript. MR participated in data collection, interpreted the results and drafted the manuscript. LJ and RD extracted the data and performed the statistical analyses. All other authors participated in data collection and provided a critical review of the manuscript.

Funding the e-Ultimaster registry was sponsored by Terumo. Terumo is the manufacturer of the Ultimaster stent.

Competing interests The following authors declare a competing interest with Terumo, the sponsor of the study: JP declared consulting fees; MM declared consulting fees and research grants; AA declared consulting fees; MA declared consulting fees; SK declared consulting fees; DJRH-S declared speaking fees and research grants; MR declared research grants. LJ and RD are employees of Terumo. All other authors have nothing to disclose.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants. The study protocol was reviewed and approved by the Institutional Review Board/Ethics Committee of each participating centre (378 hospitals from 50 countries). A complete list with all reference numbers/ID can be obtained on request. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Data also uploaded as online supplemental material.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and

responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Mamas Mamas <http://orcid.org/0000-0001-9241-8890>

Soichi Kuramitsu <http://orcid.org/0000-0001-9927-9686>

David Hildick-Smith <http://orcid.org/0000-0002-9315-3529>

Marco Roffi <http://orcid.org/0000-0002-3051-0170>

REFERENCES

- McDermott KW, Freeman WJ, Elixhauser A. Overview of operating room procedures during inpatient stays in U.S. hospitals, 2014: statistical brief #233. In: *Healthcare cost and utilization project (HCUP) statistical Briefs*. Rockville (MD: Agency for Healthcare Research and Quality (US), 2006.
- Thomas MP, Parzynski CS, Curtis JP, et al. Percutaneous coronary intervention utilization and appropriateness across the United States. *PLoS One* 2015;10:e0138251.
- Zhao R, Xu K, Li Y, et al. Percutaneous coronary intervention in patients with acute coronary syndrome in Chinese military hospitals, 2011–2014: a retrospective observational study of a national registry. *BMJ Open* 2018;8:e023133.
- Szumner K, Wallentin L, Lindhagen L, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. *Eur Heart J* 2017;38:3056–65.
- Serruys PW, Morice M-C, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009;360:961–72.
- Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. *N Engl J Med Overseas Ed* 2016;375:2223–35.
- Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med* 2020;382:1395–407.
- Saito S, Valdes-Chavarri M, Richardt G, et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the century II (clinical evaluation of new Terumo drug-eluting coronary stent system in the treatment of patients with coronary artery disease) trial. *Eur Heart J* 2014;35:2021–31.
- Wijns W, Valdes-Chavarri M, Richardt G, et al. Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the century II randomised clinical trial. *EuroIntervention* 2018;14:e343–51.
- Chisari A, Pistrutto AM, Piccolo R, et al. The Ultimaster biodegradable-polymer sirolimus-eluting stent: an updated review of clinical evidence. *Int J Mol Sci* 2016;17. doi:10.3390/ijms17091490. [Epub ahead of print: 06 Sep 2016].
- Valdes-Chavarri M, Kedev S, Neskovic AN, et al. Randomised evaluation of a novel biodegradable polymer-based sirolimus-eluting stent in ST-segment elevation myocardial infarction: the master study. *EuroIntervention* 2019;14:1836–42.
- Inohara T, Kohsaka S, Spertus JA, et al. Comparative trends in percutaneous coronary intervention in Japan and the United States, 2013 to 2017. *J Am Coll Cardiol* 2020;76:1328–40.
- Goodman SG, Nicolau JC, Requena G, et al. Longer-term oral antiplatelet use in stable post-myocardial infarction patients: insights from the long Term risk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISEase (TIGRIS) observational study. *Int J Cardiol* 2017;236:54–60.
- Urban P, Abizaid A, Banning A, et al. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (multi-center post-market surveillance) registry. *J Am Coll Cardiol* 2011;57:1445–54.
- Gao C, Takahashi K, Garg S, et al. Regional variation in patients and outcomes in the global leaders trial. *Int J Cardiol* 2021;324:30–7.
- Ibanez B, James S, Agewall S. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2017;38:2120–54.
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020;41:407–77.
- Collet J-P, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2021;42:1289–367.
- Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J* 2019;40:87–165.
- Valgimigli M, Bueno H, Byrne RA. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2017;39:213–60.
- Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. *BMJ* 2015;350:h1618.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2020;41:1111–88.
- Vynckier P, Ferrannini G, Rydén L, et al. Medical treatment in coronary patients: is there still a gender gap? results from European Society of Cardiology EUROASPIRE V registry. *Cardiovasc Drugs Ther* 2021;35:801–8.
- Tran DT, Barake W, Galbraith D, et al. Total and cause-specific mortality after percutaneous coronary intervention: observations from the Alberta provincial project for outcome assessment in coronary heart disease registry. *CJC Open* 2019;1:182–9.
- Ho PM, O'Donnell CI, Bradley SM, et al. 1-year risk-adjusted mortality and costs of percutaneous coronary intervention in the Veterans Health Administration: insights from the VA CART Program. *J Am Coll Cardiol* 2015;65:236–42.